Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19254402 | Zonal and Targeted Methods and Uses for Treating a Chronic Post-Traumatic Headache Associated with a Post-Traumatic Stress Disorder | June 2025 | October 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19059018 | Zonal and Targeted Methods and Uses for Treating a Post-Traumatic Stress Disorder | February 2025 | June 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18599428 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | March 2024 | August 2024 | Allow | 5 | 3 | 0 | Yes | No |
| 18594617 | SYNTHESIS OF BETA-HYDROXYISOVALERATE AND METHODS OF USE | March 2024 | December 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18421205 | Orally Ingestible Delivery System | January 2024 | April 2025 | Allow | 14 | 1 | 0 | No | No |
| 18416049 | Selection and Use of Melatonin Supporting Bacteria to Reduce Infantile Colic | January 2024 | January 2026 | Allow | 24 | 2 | 1 | Yes | No |
| 18493590 | ACONITIC ACID EXPORTER (AEXA) INCREASES ORGANIC ACID PRODUCTION IN ASPERGILLUS | October 2023 | May 2025 | Allow | 18 | 2 | 0 | Yes | No |
| 18467280 | METHOD FOR PREPARING A TRANSFORMED, SALMO SALAR INTERFERON GAMMA (IFNG)-PRODUCING LACTOCOCCUS LACTIS BACTERIUM | September 2023 | January 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18467511 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | September 2023 | October 2025 | Allow | 25 | 3 | 0 | Yes | No |
| 18244279 | INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES | September 2023 | January 2026 | Abandon | 29 | 2 | 1 | No | No |
| 18358046 | METHOD FOR IMPROVING GUT MICROBIOTA WITH LACTIPLANTIBACILLUS PLANTARUM TCI837 | July 2023 | October 2024 | Allow | 15 | 2 | 0 | No | No |
| 18345619 | STABLE BACTERIAL EXTRACTS AS PHARMACEUTICALS | June 2023 | March 2025 | Abandon | 20 | 2 | 0 | No | No |
| 18338189 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | June 2023 | January 2024 | Allow | 6 | 1 | 0 | No | No |
| 18183262 | METHOD FOR TREATMENT AND CONTROL OF PLANT DISEASE | March 2023 | February 2024 | Allow | 11 | 1 | 0 | No | No |
| 18005816 | APPLICATION OF MICROBIAL GLYCOSIDASE AS AN ANTI-VIRAL THERAPEUTIC, PROGNOSTIC, AND DIAGNOSTIC | January 2023 | March 2026 | Allow | 38 | 3 | 1 | Yes | No |
| 18011014 | METHODS FOR MANUFACTURING ADAS | December 2022 | March 2026 | Abandon | 39 | 1 | 1 | No | No |
| 18010876 | READY-TO-USE PROBIOTIC COMPOSITIONS AND USES THEREOF | December 2022 | December 2025 | Abandon | 36 | 1 | 1 | No | No |
| 18077484 | Composition and Kit for colonization in gut of external probiotics through bioorthogonal click chemistry | December 2022 | January 2026 | Abandon | 37 | 6 | 1 | No | No |
| 17996709 | SELECTIVE MEDIA FOR DETECTION OF ZYGOSACCHAROMYCES | October 2022 | November 2025 | Abandon | 37 | 1 | 1 | No | No |
| 18045822 | MICROORGANISM WITH INCREASED CARBON MONOXIDE AVAILABILITY AND 2,3-BDO PRODUCTION USING THE SAME | October 2022 | July 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17793249 | COMPOSITIONS AND METHODS FOR CONTROLLING UNDESIRABLE MICROBES AND IMPROVING ANIMAL HEALTH | July 2022 | October 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17825386 | COMPOSITIONS AND METHODS FOR DIETARY MANAGEMENT OF IMMUNE HEALTH | May 2022 | January 2024 | Abandon | 20 | 1 | 1 | No | No |
| 17658217 | SYNTHESIS OF BETA-HYDROXYISOVALERATE AND METHODS OF USE | April 2022 | October 2023 | Allow | 18 | 1 | 1 | Yes | No |
| 17762332 | METHODS FOR DETERMINING GROWTH AND RESPONSE | March 2022 | November 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17693309 | METHOD OF TESTTING INHIBITORY EFFECT OF CARBON DIOXIDE ON SPOILAGE CAUSING ABILITY OF SHEWANELLA PUTREFACIENS | March 2022 | May 2023 | Abandon | 14 | 1 | 0 | No | No |
| 17681321 | Methicillin-Resistant Staphylococcus Aureus Mutant Strain And Use Thereof | February 2022 | March 2024 | Abandon | 25 | 2 | 1 | No | No |
| 17670982 | SALUTARY EFFECTS OF INDIGENOUS PROBIOTICS AND NANOAEROSOL METHODS TO MITIGATE MICROBIAL INFECTIONS INCLUDING COVID 19 | February 2022 | August 2023 | Abandon | 18 | 1 | 1 | No | No |
| 17568444 | Protein-based multifunctional molecular switch for antibody detection | January 2022 | August 2024 | Abandon | 32 | 2 | 1 | Yes | No |
| 17564250 | LACTIPLANTIBACILLUS PLANTARUM TCI837, METHODS FOR USING THE SAME, AND IRON SUPPLEMENT COMPOSITION HAVING THE SAME | December 2021 | April 2023 | Allow | 16 | 1 | 1 | No | No |
| 17558025 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | December 2021 | June 2023 | Allow | 18 | 1 | 1 | No | No |
| 17554626 | METHOD OF REDUCING TOBACCO ADDICTION IN SMOKING SUBJECT WITH LACTOBACILLUS FERMENTUM GKF3 | December 2021 | June 2023 | Allow | 18 | 2 | 0 | Yes | No |
| 17554463 | Iron-reducing Tessaraccocus Oleiagri Strain DH10 and Applications thereof | December 2021 | March 2024 | Abandon | 27 | 3 | 0 | No | No |
| 17553491 | PHARMACEUTICAL COMPOSITION AND HEALTH FUNCTIONAL FOOD FOR PREVENTING, AMELIORATING OR TREATING THROMBOSIS CONTAINING EXTRACT OF VESPA VELUTINA NIGRITHORAX AS ACTIVE INGREDIENT | December 2021 | March 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17548806 | COMPOSITION FOR MODULATING IMMUNITY AND THE USE THEREOF | December 2021 | October 2024 | Allow | 34 | 3 | 1 | No | No |
| 17540349 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | December 2021 | April 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17616088 | COMPOSITION CONTAINING ENTEROCOCCUS FAECALIS AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING OBESITY OR METABOLIC SYNDROMES INDUCED THEREBY | December 2021 | April 2025 | Allow | 40 | 2 | 0 | Yes | No |
| 17535982 | METHODS OF DIAGNOSING AND TREATING MULTIPLE SCLEROSIS WITH VASCULAR ENDOTHELIAL BIOMARKERS | November 2021 | May 2024 | Abandon | 30 | 1 | 1 | Yes | No |
| 17530430 | RECOMBINANT ENDOXYLANASES AND RELATED COMPOSITIONS AND METHODS OF USE | November 2021 | May 2024 | Abandon | 30 | 2 | 1 | Yes | No |
| 17453573 | DRUG FOR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CAUSED BY CORONAVIRUS AND COMPLICATIONS THEREOF AND USE OF THE DRUG | November 2021 | February 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17507964 | METHOD FOR PREPARING NATURAL VANILLIN VIA BIOOXIDATION 4-METHYLGUAIACOL | October 2021 | July 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17505411 | HEME-CONTAINING CELL CULTURE MEDIA AND USES THEREOF | October 2021 | March 2025 | Abandon | 41 | 4 | 1 | No | No |
| 17497582 | METHOD FOR TREATMENT AND CONTROL OF PLANT DISEASE | October 2021 | December 2023 | Allow | 26 | 2 | 0 | No | No |
| 17474242 | STABLE BACTERIAL EXTRACTS AS PHARMACEUTICALS | September 2021 | August 2023 | Allow | 23 | 3 | 0 | Yes | No |
| 17466389 | METHODS FOR HEAT-ASSISTED ENZYME DIGESTION | September 2021 | April 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17433755 | COMPOSITION FOR INDUCING PILI FORMATION IN BACTERIUM OF GENUS BIFIDOBACTERIUM | August 2021 | December 2024 | Allow | 39 | 4 | 0 | Yes | No |
| 17432630 | PRODUCTION OF NATURAL ORGANIC GLUCONATES | August 2021 | September 2025 | Allow | 49 | 4 | 0 | Yes | No |
| 17406266 | CARBAPENEMASES FOR USE WITH ANTIBIOTICS FOR THE PROTECTION OF THE INTESTINAL MICROBIOME | August 2021 | December 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17405720 | PROTECTION AGAINST CORONAVIRUS INFECTION BY EXTRACTS AND EXTRACT COMPONENTS | August 2021 | December 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17394044 | COMPOSITIONS AND METHODS FOR TREATING WOUNDS IN LIVESTOCK | August 2021 | January 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17425691 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING BACILLUS AMYLOLIQUEFACIENS | July 2021 | August 2025 | Abandon | 49 | 6 | 0 | No | No |
| 17424291 | COMPOSITIONS AND METHODS FOR INCREASING THE VIABILITY OF FREEZE-DRIED PROBIOTICS | July 2021 | October 2025 | Abandon | 50 | 4 | 1 | Yes | No |
| 17372236 | CELL BASED METHOD FOR DETERMINATION OF BOTULINUM TOXIN POTENCY BASED ON WESTERN BLOTTING | July 2021 | August 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 17421717 | PRODUCT DERIVED FROM RHODOCOCCUS RUBER, AND PHARMACEUTICAL USE THEREOF | July 2021 | August 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17366757 | ROBUST SELF-REGENERATABLE STIFF LIVING MATERIALS | July 2021 | July 2023 | Allow | 25 | 2 | 1 | No | No |
| 17420122 | FORMULATION FOR PROTECTION AGAINST KIWI BACTERIOSIS, CAUSED BY THE BACTERIUM PSEUDOMONAS SYRINGAE PV. ACTINIDIAE (PSA) | June 2021 | May 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17358856 | Reverse transcriptase with increased enzyme activity and application thereof | June 2021 | January 2026 | Abandon | 54 | 4 | 1 | No | No |
| 17355547 | SERINE HYDROLASE PROFILING ASSAY IN BIOTHERAPEUTICS | June 2021 | August 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17415989 | PROCESS FOR TREATING LIGNOCELLULOSIC BIOMASS | June 2021 | July 2025 | Allow | 49 | 3 | 1 | Yes | No |
| 17347109 | ACONITIC ACID EXPORTER (AEXA) INCREASES ORGANIC ACID PRODUCTION IN ASPERGILLUS | June 2021 | July 2023 | Allow | 25 | 1 | 1 | No | No |
| 17303916 | TREHALOSE PHOSPHORYLASE | June 2021 | August 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17342578 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | June 2021 | January 2024 | Abandon | 31 | 0 | 1 | No | No |
| 17311464 | HOMING ENDONUCLEASE VARIANTS | June 2021 | March 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17338388 | Zonal and Targeted Methods and Uses for Treating a Migraine Disorder | June 2021 | October 2024 | Allow | 41 | 3 | 1 | No | No |
| 17297383 | ENGINEERED BIOSYNTHETIC PATHWAYS FOR PRODUCTION OF 1,5-DIAMINOPENTANE BY FERMENTATION | May 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17297371 | ENGINEERED BIOSYNTHETIC PATHWAYS FOR PRODUCTION OF 2-OXOADIPATE BY FERMENTATION | May 2021 | August 2024 | Abandon | 39 | 2 | 0 | No | No |
| 17331174 | MEDIA SUPPLEMENTS AND METHODS TO CULTURE HUMAN GASTROINTESTINAL ANAEROBIC MICROORGANISMS | May 2021 | June 2025 | Abandon | 49 | 3 | 0 | Yes | No |
| 17296218 | CYCLOHEXENECARBOXYLATE ESTER HYDROLASE, AND MUTANT, CODING GENE, EXPRESSION VECTOR, RECOMBINANT BACTERIUM AND USE THEREOF | May 2021 | August 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17295736 | Proteins for Blocking Neurotransmitter Release | May 2021 | August 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17294032 | BACILLUS THURINGIENSIS STRAINS AND METHODS FOR CONTROLLING PESTS | May 2021 | August 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17292683 | BACILLUS SP. PROBIOTIC STRAINS AND MUTATIONS | May 2021 | July 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17314541 | METHODS FOR HEAT-ASSISTED ENZYME DIGESTION | May 2021 | September 2024 | Allow | 40 | 2 | 0 | No | No |
| 17246837 | ARTHROSPIRA PLATENSIS NON-PARENTERAL THERAPEUTIC DELIVERY PLATFORM | May 2021 | July 2025 | Allow | 51 | 5 | 1 | Yes | No |
| 17236928 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | April 2021 | December 2024 | Allow | 44 | 3 | 0 | Yes | No |
| 17285605 | ANTIBODY FOR HAIR IMPROVEMENT USE | April 2021 | January 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17221810 | MICROBIAL OILS WITH HIGH LEVELS OF OMEGA-3 FATTY ACIDS | April 2021 | March 2025 | Allow | 47 | 5 | 1 | Yes | No |
| 17220684 | ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES | April 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17219119 | METHODS AND COMPOSITIONS RELATED TO MODIFIED GREEN FLUORESCENT PROTEIN (GFP) WITH AN EMBEDDED FOREIGN PEPTIDE | March 2021 | March 2025 | Allow | 47 | 4 | 1 | Yes | No |
| 17280891 | STREPTOMYCES SP. SNC087 STRAIN ISOLATED FROM SEAWATER, METHOD FOR PRODUCING STAUROSPORINE USING SAME, METHOD OF CULTURING SAME, AND PURE CULTURE MEDIUM OF SAME | March 2021 | October 2023 | Allow | 31 | 1 | 0 | No | No |
| 17272618 | PROCESS FOR PRODUCING A RECOMBINANT FRAGMENT OF THE C-TERMINAL REGION OF THE FLAVIVIRUS NONSTRUCTURAL SOLUBLE PROTEIN NS1, PURIFICATION PROCESS, PRODUCT, USE OF THE PRODUCT, METHOD OF DETECTION AND METHOD OF DIAGNOSIS | March 2021 | March 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17188139 | Acetylation of Miro1 | March 2021 | September 2025 | Allow | 55 | 5 | 1 | Yes | No |
| 17187778 | ACTIVITY BASED HOST CELL PROTEIN PROFILING | February 2021 | August 2024 | Allow | 41 | 2 | 1 | Yes | Yes |
| 17271958 | TRICHODERMA REESEI MUTANT STRAIN, AND METHOD OF PRODUCING PROTEIN | February 2021 | April 2023 | Allow | 25 | 1 | 1 | No | No |
| 17175265 | BIOMARKERS THAT INDICATE INFECTION WITH COCCIDIOIDES | February 2021 | September 2025 | Allow | 55 | 5 | 0 | Yes | No |
| 17267050 | LACTIC ACID BACTERIUM, BLOOD IRON INCREASING AGENT, AND ANEMIA IMPROVING AGENT | February 2021 | June 2024 | Allow | 40 | 2 | 0 | No | No |
| 17161796 | METHODS FOR WHOLE-CELL GLYCOPROTEOMIC ANALYSIS | January 2021 | August 2025 | Abandon | 55 | 4 | 1 | No | No |
| 17153896 | APPARATUS FOR DETECTION OF PROTEOLYTIC ACTIVITY IN A BIOLOGICAL SAMPLE | January 2021 | July 2023 | Allow | 29 | 2 | 1 | No | No |
| 17258862 | VIRAL-VECTORED VACCINE FOR MALARIA | January 2021 | September 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17258377 | RIBOSOME VARIANTS FOR SEQUENCE DEFINED POLYMER SYNTHESIS | January 2021 | May 2025 | Allow | 52 | 3 | 0 | Yes | No |
| 17052116 | REAGENT TO LABEL PROTEINS VIA LYSINE ISOPEPTIDE BONDS | October 2020 | December 2022 | Allow | 25 | 1 | 1 | Yes | No |
| 17082082 | SYSTEMS AND METHODS FOR THERMAL MANAGEMENT OF OUTDOOR ALGAE CULTIVATION | October 2020 | April 2025 | Abandon | 53 | 3 | 1 | Yes | No |
| 17075030 | ORALLY INGESTIBLE DELIVERY SYSTEM | October 2020 | October 2023 | Allow | 36 | 1 | 1 | No | No |
| 17073088 | Transparent Cellulose-Based Materials and Methods of Making the Same | October 2020 | November 2023 | Abandon | 37 | 2 | 1 | Yes | No |
| 17046397 | GINGIVITIS DIAGNOSTIC METHODS, USES AND KITS | October 2020 | March 2025 | Abandon | 53 | 2 | 1 | Yes | No |
| 17039153 | ELECTROCONDUCTIVE DECELLULARIZED EXTRACELLULAR MATRIX COMPOSITIONS FOR PREPARATION OF ENGINEERED TISSUES AND RELATED METHODS | September 2020 | July 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17042738 | BIOMARKER AND TREATMENT TARGET FOR ALCOHOLIC HEPATITIS | September 2020 | August 2025 | Allow | 59 | 2 | 1 | Yes | No |
| 17005913 | ENGINEERED LIPASE VARIANTS | August 2020 | January 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 16937692 | IDENTIFICATION OF VIABLE HUMAN EMBRYOS | July 2020 | August 2024 | Allow | 49 | 5 | 0 | Yes | No |
| 16963079 | Inert Carrier Salmonella and Potential Use Thereof | July 2020 | July 2024 | Allow | 48 | 3 | 0 | Yes | No |
| 16962980 | METHOD FOR DETERMINING MICROORGANISM CONCENTRATION | July 2020 | January 2025 | Abandon | 54 | 2 | 1 | No | No |
| 16961598 | Selection and Use of Melatonin Supporting Bacteria to Reduce Infantile Colic | July 2020 | October 2023 | Allow | 39 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SWIFT, CANDICE LEE.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SWIFT, CANDICE LEE works in Art Unit 1657 and has examined 87 patent applications in our dataset. With an allowance rate of 54.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner SWIFT, CANDICE LEE's allowance rate of 54.0% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SWIFT, CANDICE LEE receive 2.28 office actions before reaching final disposition. This places the examiner in the 64% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SWIFT, CANDICE LEE is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +40.3% benefit to allowance rate for applications examined by SWIFT, CANDICE LEE. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.5% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 27.3% of cases where such amendments are filed. This entry rate is in the 38% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.3% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.